Analysis of 13 cases of rhabdomyosarcoma in the female genital tract
- Author:
- No author available
- Journal Title:
- 中华妇产科杂志
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.0529-567x.2016.04.005
- Key Word:
- 生殖器肿瘤,女(雌)性;横纹肌肉瘤;药物疗法;妇科外科手术;预后;Genital neoplasms,female;Rhabdomyosarcoma;Drug therapy;Gynecologic surgical procedures;Prognosis
Abstract： Objective To investigate the clinical features, treatments and prognostic factors of rhabdomyosarcoma (RMS) in the female genital tract. Methods A retrospective analysis was performed on 13 cases of RMS in the female genital tract. Clinical characteristics, treatments and prognosis were compared and analyzed statistically. Results The median age was 21.0 years (range, 6 to 54 years). There were 6 cases vaginal RMS and 7 cases cervical RMS, included 11 cases of embryonal RMS (ERMS) and 2 cases of alveolar RMS (ARMS). According to the Federation International of Gynecology and Obstetrics (FIGO)staging system,there were 6 cases of stageⅠ, 3 cases of stageⅡ, 1 case of stageⅢand 3 cases of stage Ⅳ, the median survival time were respectively 112.5, 153.0, 9.0 and 3.5 months. According to the Intergroup Rhabdomyosarcom Study Group (IRSG) staging system, there were 10 cases of stageⅠ and 3 cases of the stage Ⅳ, and their median survival time were respectively 112.5 and 3.5 months. Nine patients received surgery and the median survival time was 108.0 months (range, 9 to 228 months), 6 of them received chemotherapy after surgery and the median survival time was 152.0 months (range, 9 to 228 months), the other 3 cases did not receive any therapy after surgery and the median survival time was 25.0 months (range, 9 to 108 months). Four patients did not receive surgery and the median survival time was 6.3 months (range, 1 to 117 months). There were 2 cases received combined treatment included radiotherapy and the survival time were respectively 4 and 198 months. There were 8 cases who was survival without disease and 5 cases died of cancer. The median survival time in 13 patients was 25.0 months (range, 1 to 228 months) and the 5-year overall survival rate was 58.6%. Conclusions The prognosis of early stage of RMS in the female genital tract is good. While, the prognosis of advanced stage is poor. The standard treatment strategy is combination of surgery and chemotherapy,whether radiotherapy could improve the prognosis still need further study.
- [1]徐莹,唐锁勤,王建文,等.13例小儿横纹肌肉瘤疗效分析[J].2008,(2).
- [2]Raney RB,Meza JL,Fryer C,etc.Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.[J].2001,19(12).
- [3]W A, Newton,E A, Gehan,B L, Webber,etc.Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification--an Intergroup Rhabdomyosarcoma Study.[J].1995,76(6).
- [4]Gianni Bisogno,Alessia Compostella,Andrea Ferrari,etc.Rhabdomyosarcoma in adolescents: A report from the AIEOP Soft Tissue Sarcoma Committee[J].2012,118(3).
- [5]David M, Parham,Dale A, Ellison.Rhabdomyosarcomas in adults and children: an update.[J].2006,130(10).
- [6]Wiener ES,Link MP,Grier HE,etc.Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV.[J].2000,18(12).
- [7]W, Lawrence,J R, Anderson,E A, Gehan,etc.Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group.[J].1997,80(6).
- [8]Makimoto A,Kaneta T,Hosono A,etc.Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.[J].2009,23(2).
- [9]Meyer WH,Hawkins DS,Neglia JP,etc.Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group.[J].2008,50(1).
- [10]Frumovitz,M.,Kriseman,M.L.,Wang,W.-L.,etc.Rhabdomyosarcoma of the cervix in adult women and younger patients[J].2012,126(3).
- [11]VanGaal,J.C.,DeBont,E.S.J.M.,vanderGraaf,W.T.A.,etc.Building the bridge between rhabdomyosarcoma in children, adolescents and young adults: The road ahead[J].2012,82(3).
- [12]Andrea, Ferrari,Palma, Dileo,Michela, Casanova,etc.Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution.[J].2003,98(3).
- [13]Sultan I,Qaddoumi I,Yaser S.Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients.[J].2009,27(20).
- [14]H M, Maurer,M, Beltangady,E A, Gehan,etc.The Intergroup Rhabdomyosarcoma Study-I. A final report.[J].1988,61(2).
- [15]Hawkins DS,Arndt CA,Stoner JA.Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.[J].2009,27(31).
- [16]Rey A,Bisogno G,Stevens MC,etc.Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.[J].2008,26(14).
- [17]Dehner,L.P.,Hill,D.A.,Jarzembowski,J.A..Embryonal rhabdomyosarcoma of the uterine cervix: A report of 14 cases and a discussion of its unusual clinicopathological associations[J].2012,25(4).
- [18]Nasir A,Gnepp DR,Perry KD,etc.Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.[J].2009,40(3).
- [19]Chen,Z.,Sutter,A.L.,Esiashvili,N.,etc.Radiation therapy target volume reduction in pediatric rhabdomyosarcoma: Implications for patterns of disease recurrence and overall survival[J].2013,119(8).
- [20]Crist W,Gehan EA,Ragab AH,etc.The Third Intergroup Rhabdomyosarcoma Study.[J].1995,13(3).
- [21]L B, Kenney,M R, Laufer,F D, Grant,etc.High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood.[J].2001,91(3).